We are proud to be members of Lung Cancer Europe – Oncogene Cancer Research
Oncogene Cancer Research recently shared a post by Lung Cancer Europe on LinkedIn, adding:
“We are proud to be members of Lung Cancer Europe and work together with the 40+ member organizations to represent the voice of Europeans impacted by lung cancer, improving equity in access to optimal care, outcomes, and quality of life.”
Quoting Lung Cancer Europe’s post:
“New LuCE Member: Oncogene Cancer Research
We are pleased to announce that the UK’s Oncogene Cancer Research has now joined the LuCE family.
Its mission is to increase the life expectancy of people living with oncogene-driven cancers that originate in the lungs.
Each year hundreds of thousands of people are diagnosed with oncogene-driven lung cancer such as ALK, EGFR, RET, ROS1, KRAS, and others.
Those diagnosed are often younger and many have no known risk factors. These oncogene-driven cancers can also appear elsewhere in the body and benefit from many of the same drugs.
Oncogene Cancer Research is focused on funding research to increase life expectancy – and one day find a cure.
They have a growing number of members and its senior representatives include:
- Yvonne Diaz, Chair and Co-founder
- Jan Clark, Secretary and Co-founder
- Helen Tankard, Trustee.”
Read further
Sources: Oncogene Cancer Research/LinkedIn and Lung Cancer Europe/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023